Sildalist is a prescription pill that contains two phosphodiesterase-type 5 (PDE5) inhibitors-sildenafil and tadalafil-as its active components. The combination is formulated in a fixed-strength tablet of 100 mg sildenafil / 20 mg tadalafil. It belongs to the therapeutic class of erectile dysfunction (ED) medications and is regulated as a prescription drug in Hong Kong by the Department of Health.
This article is based on the known properties of sildenafil and tadalafil, a class of ED medications, and provides evidence-based information for adult patients.
Sildenafil and tadalafil belong to the same drug class (PDE5 inhibitors) but have slightly different pharmacokinetic profiles.
Sildenafil blocks the enzyme PDE5, which normally degrades cyclic guanosine monophosphate (cGMP). By inhibiting PDE5, sildenafil increases cGMP levels in the smooth muscle of the penile arteries, promoting relaxation and blood flow when sexual stimulation triggers nitric oxide release.
Tadalafil also inhibits PDE5, leading to the same rise in cGMP. Its longer half-life (approximately 17 hours) provides a more prolonged window of activity compared with sildenafil (half-life ≈ 4 hours).
When taken together, the two agents reinforce the cGMP pathway, potentially offering both rapid onset (from sildenafil) and extended duration (from tadalafil). Onset of action typically begins within 30-60 minutes, with peak effects occurring around 1-2 hours after ingestion. The combined effect can last up to 36 hours, reflecting tadalafil’s longer duration.
Both active ingredients are approved by major regulatory agencies for the treatment of erectile dysfunction. In Hong Kong, the Department of Health classifies each as a prescription medication indicated for men who have difficulty achieving or maintaining an erection sufficient for satisfactory sexual performance.
Because Sildalist contains a fixed combination of the two agents, it is intended for men who may benefit from the rapid onset of sildenafil together with the extended therapeutic window of tadalafil. The decision to use this combination should be made by a qualified healthcare professional after evaluating the patient’s medical history and treatment goals.
Pulmonary arterial hypertension (PAH): Sildenafil is approved for PAH in several jurisdictions. Tadalafil also has a PAH indication. Use of the combination for PAH is not approved and would be considered off-label.
Benign prostatic hyperplasia (BPH): Tadalafil alone is approved for BPH symptom relief. There is limited evidence that adding sildenafil does not provide additional benefit for BPH.
Disclaimer: Off-label use requires medical supervision and individualized risk assessment. Patients should discuss potential benefits and risks with their prescriber.
These effects are usually mild, transient, and resolve without medical intervention. If they persist or worsen, patients should contact their healthcare provider.
Patients should inform their healthcare provider of all prescription medicines, over-the-counter drugs, herbal supplements, and vitamins before starting Sildalist.
Important: Dosing must be individualized by a qualified healthcare professional. The information above is for educational purposes only and does not replace personalized medical advice.
Routine monitoring for patients on Sildalist includes:
For most men, additional laboratory tests are not required unless comorbid conditions (e.g., renal or hepatic disease) dictate otherwise.
This article provides educational information about Sildalist and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Drinking alcohol in moderation is generally safe, but excessive intake can increase the risk of dizziness, hypotension, and reduced erectile response. It is advisable to limit alcohol consumption on days you plan to use the medication.
Sildenafil provides a quicker onset of action (usually within 30 minutes), while tadalafil offers a longer duration of effect (up to 36 hours). The fixed-dose combination aims to give both rapid onset and extended coverage, but exact benefits vary among individuals and should be assessed by a prescriber.
A prolonged erection (priapism) is a medical emergency. Seek immediate medical attention; prompt treatment can prevent permanent tissue damage.
Sildalist tablets are typically white, oval-shaped, and imprinted with “100/20”. Appearance may differ slightly depending on the manufacturer and regional packaging.
Most patients can safely perform these activities. However, if you experience dizziness, visual disturbances, or significant hypotension, you should refrain from driving until symptoms resolve.
Coverage depends on individual health plans and the prescribing physician’s justification. Patients should verify reimbursement details with their insurance provider or the Hospital Authority.
The dosing schedule is individualized. Some clinicians prescribe it for daily use to maintain erectile capacity, while others advise use only before anticipated sexual activity. Follow your prescriber’s instructions.
There are no specific food bans, but a high-fat meal may slow the absorption of sildenafil, slightly delaying its effect. Taking the tablet with a light meal can help achieve more consistent results.
The most critical interaction is with nitrates, which can cause severe hypotension. Other notable interactions include potent CYP3A4 inhibitors (e.g., ketoconazole) and certain alpha-blockers. Always disclose all medications to your prescriber.
Expiration dates are printed on each package and typically range from 24 to 36 months from the manufacturing date, provided the tablets are stored at room temperature away from moisture and heat.
